BTIG upgraded Embecta (EMBC) to Buy from Neutral with a $26 price target Shares gained about 30% in Tuesday trading as investors rewarded ...

BofA raised the firm’s price target on Embecta (EMBC) to $20 from $17 and keeps an Underperform rating on the shares after the company ...

Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...

After adding nearly 30% in the previous session following its better-than-expected Q4 results for FY24, Embecta (NASDAQ:EMBC) ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.

Q4 2024 Earnings Call Transcript November 26, 2024 Embecta Corp. misses on earnings expectations. Reported EPS is $ EPS, ...

Embecta Corp (EMBC) reports a 4.1% revenue increase while navigating restructuring and future growth opportunities.

PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference ...

AQR Capital Management LLC lifted its stake in shares of Embecta Corp. (NASDAQ:EMBC – Free Report) by 136.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC.

embecta Corp. (embecta) (Nasdaq: EMBC), a global diabetes care company, visits the Nasdaq MarketSite in Times Square today in recognition of National Diabetes Awareness Month in November.